| Humira (adalimumab) / AbbVie |
NCT00193648: Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) |
|
|
| Completed | 1 | 21 | US | Rosiglitazone (Avandia), Adalimumab (Humira) | Northwell Health, University of North Carolina, The Cleveland Clinic | Focal Glomerulosclerosis | | 10/07 | | |
NCT00650156: Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis |
|
|
| Completed | 1 | 24 | RoW | adalimumab, ABT-D2E7, Humira | AbbVie | Rheumatoid Arthritis | 10/07 | | | |
NCT00421642: Open-Label Adalimumab for Ulcerative Colitis Patients |
|
|
| Completed | 1 | 20 | US | Adalimumab, Humira | Mayo Clinic | Ulcerative Colitis | 04/08 | 04/08 | | |
NCT02252809: Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects |
|
|
| Completed | 1 | 51 | Europe | adalimumab, methylprednisolone | Brugmann University Hospital | Innate Immunity | 04/09 | 07/09 | | |
ADA01, NCT00855608: Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study |
|
|
| Unknown status | 1 | 15 | RoW | adalimumab, Humira | Rafic Hariri University Hospital, American University of Beirut Medical Center | Uveitis, Diabetic Retinopathy, Choroidal Neovascularization | 03/13 | 03/13 | | |
NCT01899755: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. |
|
|
| Completed | 1 | 45 | Europe | GSK2800528, solution for injection, Placebo (0.9% w/v Sodium Chloride), solution for injection, Adalimumab, solution for injection | GlaxoSmithKline | Psoriasis | 04/14 | 04/14 | | |
NCT02206867: Pharmacokinetics and Safety Study of LBAL in Healthy Subjects |
|
|
| Completed | 1 | 116 | RoW | LBAL, Adalimumab, Humira | LG Life Sciences | Healthy Subjects | 02/15 | 02/15 | | |
TAM-RT, NCT02516774: A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers |
|
|
| Withdrawn | 1 | 0 | Europe | Adalimumab, Humira® | Gustave Roussy, Cancer Campus, Grand Paris | Anaplastic Thyroid Cancers | 12/15 | 12/15 | | |
NCT03273192: A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects |
|
|
| Completed | 1 | 74 | RoW | Adalimumab, CinnoRA, Humira | Cinnagen | Bioequivalence, Phase 1 | 08/17 | 08/17 | | |
NCT02912247: Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers |
|
|
| Completed | 1 | 183 | NA | human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab | Innovent Biologics (Suzhou) Co. Ltd. | Healthy | 09/17 | 09/17 | | |
NCT03254810: Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects |
|
|
| Completed | 1 | 94 | RoW | SYN060, Adalimumab North American source, Adalimumab European source | Synermore Biologics Co., Ltd. | Arthritis, Rheumatoid | 07/18 | 07/18 | | |
ALVOPAD, NCT03579823: Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers |
|
|
| Completed | 1 | 24 | RoW | Adalimumab 100 MG/ML [Humira], AVT02 100MG/ML | Alvotech Swiss AG | Healthy Volunteers | 08/18 | 08/18 | | |
NCT03917628: Pharmacokinetics and Safety in Healthy Volunteers |
|
|
| Completed | 1 | 146 | RoW | SCT630, adalimumab-EU source | Sinocelltech Ltd. | Healthy | 11/19 | 11/19 | | |
NCT03983876: PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) |
|
|
| Completed | 1 | 207 | RoW | Adalimumab, Humira ATC code L04AB0 | Alvotech Swiss AG | Phase 1 | 12/19 | 12/19 | | |
NCT04439929: Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects |
|
|
| Completed | 1 | 168 | Europe | TUR01, Adalimumab-Turgut, Adalimumab-EU, Humira | Turgut İlaçları A.Ş. | Healthy Participants | 01/20 | 01/20 | | |
NCT03849313: Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) |
|
|
| Completed | 1 | 390 | RoW | Adalimumab, Humira ATC code L04AB04 | Alvotech Swiss AG | Healthy Volunteers | 02/20 | 02/20 | | |
ACTRN12620000932965: A Phase 1 study dosing with a Humira® (adalimumab) Enema in Patients with Active Ulcerative Colitis. |
|
|
| Terminated | 1 | 12 | | | Progenity Inc, Progenity Inc. | Ulcerative colitis | | | | |
ChiCTR2000034388: Phase I clinical study of pharmacokinetics of recombinant human anti-tumor necrosis factor (TNF - α) monoclonal antibody injection and salmeterol |
|
|
| Recruiting | 1 | 162 | | TNF-a 40mg ;humira 40mg | Phase I Clinical Laboratory of Affiliated Hospital of Changchun University of Traditional Chinese Medicine; New Drug Research&Development Company of NCPC (North China Pharmaceutical Group Corporation), National major special projects and self financing | Rheumatoid arthritis, Psoriasis, Ankylosing Spondylitis | | | | |
NCT04551352: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas |
|
|
| Completed | 1 | 20 | Europe, Canada, US, RoW | RO7293583, Tocilizumab, Actemra, Obinutuzumab, Gazyva, Adalimumab, Humira | Hoffmann-La Roche | Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma | 07/22 | 07/22 | | |
NCT05884242: A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge |
|
|
| Completed | 1 | 20 | Europe | Adalimumab, Humira, Lipopolysaccharide (LPS) | Janssen Research & Development, LLC | Healthy | 08/23 | 08/23 | | |
ChiCTR2300074787: A Multicenter, Prospective Clinical Study of the Effect of Adalimumab Trough Drug Concentration on Predicting Efficacy in Crohn's Disease |
|
|
| Recruiting | 1 | 30 | | Expected treatment regimen of adalimumab stem: Week 0, 160 mg; Week 2, 80 mg; followed by 40 mg every 2 weeks. The course of treatment was 24 weeks. | Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University, Self-financing | Crohn's disease | | | | |
NCT06742606: Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease |
|
|
| Not yet recruiting | 1 | 40 | NA | Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab | Ain Shams University | Effect of Drug | 04/26 | 12/26 | | |
NCT06926478: Subconjunctival Humira for Boston Keratoprosthesis |
|
|
| Not yet recruiting | 1 | 8 | US | Adalimumab Injection, Humira | Massachusetts Eye and Ear Infirmary | Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome | 08/27 | 08/28 | | |
